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Background: More than even before, the efficacy of epidermal 
growth factors (EGFRs) tyrosine kinase inhibitors in non–small-
cell lung cancer patients carrying EGFR wild-type tumors has been 
under investigation. EGFR wild-type patients represent a large and 
heterogeneous group of patients. In this setting, the role played by 
high polysomy of chromosome 7 still remains controversial. Indeed, 
previous reports did not discriminate between chromosome 7 high 
polysomy and EGFR amplification and/or did not investigate the 
concurrent presence of EGFR and KRas mutations.
Methods: We retrospectively collected data from 163 patients analyzed 
for EGFR status (mutation, amplification, chromosome 7 trysomy, and 
polysomy), in addition to KRas mutation, between 2000 and 2010 in our 
institute. Erlotinib was administered to 73 of them. Objective responses 
and progression-free survivals to erlotinib were evaluated.
Results: High polysomy of chromosome 7 characterized 17% (28 
of 163) of EGFR/KRas wild-type tumors, independently of smok-
ing status. In this group, 13 patients received erlotinib at progres-
sion. The treatment led one complete and four partial responses, and 
five stable diseases. Two patients progressed. One patient was lost to 
follow-up. The mean time to progression was 9 months.
Conclusion: Among the EGFR wild-type population, when analyzed 
separately, high polysomy of chromosome 7 was the only molecular 
feature conferring clear signs of sensitivity to erlotinib. Therefore, 
the evaluation of high polysomy of chromosome 7 could become a 
helpful tool to predict for the benefit from epidermal growth factors 
tyrosine kinase inhibitors in selected cases.
Key Words: Chromosome 7 high polysomy, Epidermal growth fac-
tors tyrosine wild-type, Erlotinib.
(J Thorac Oncol. 2015;10: 392–396)
More than even before, the efficacy of epidermal growth factors tyrosine kinase inhibitors (EGFR-TKI) in non–
small-cell lung cancer (NSCLC) patients carrying EGFR wild-
type tumors has been under investigation. A small proportion 
(1–20%, depending on the trial) of patients with no detectable 
EGFR-activating mutations show a radiographic response when 
treated with EGFR-TKI.1–3 This can be partially explained by 
the fact that all the molecular diagnostic tests for EGFR muta-
tions have an inherent limit of detection.4 Nevertheless, it is 
possible that other genetic alterations may activate the same 
pathway. Indeed, EGFR wild-type patients represent a large and 
heterogeneous group of patients. Within this group are included 
patients whose tumors carry multiple EGFR gene copy number 
(amplification) or multiple copy of chromosome 7, where the 
EGFR gene is located (trysomy-polysomy). Gain of EGFR copy 
number (EGFR amplification or high polysomy of chromosome 
7) was shown to be associated to EGFR-TKI sensitivity in retro-
spective studies, but the lack of paired analysis with EGFR and 
KRas mutations limited data interpretation.5–8 Moreover, data 
related to EGFR amplification or chromosome 7 high polysomy 
have never been analyzed separately.
Therefore, we retrospectively collected all the samples 
analyzed for EGFR mutation and amplification, KRas muta-
tion, and chromosome 7 copy number variations. Among the 
entire cohort of patients included within the database, we 
searched for patients who counted EGFR-TKI in their medical 
history and focused on those with EGFR wild-type tumors.
MATERIALS AND METHODS
Data Collection
Database was created by retrospectively searching for 
tumor samples analyzed for EGFR/Kras mutations and EGFR 
fluorescent in situ hybridization (FISH) at the European 
Institute of Oncology, Milan, between 2000 and 2010. 
Corresponding tumor-related data and medical history of the 
patients were recorded as well. Particular attention was used 
toward EGFR-TKI treatments, for which the dates of pro-
gression and treatment durations were accurately estimated. 
Survival data were obtained through direct patient or family 
contact or, in the cases in which this was not possible, from 
the local registry office services. Data dealing with patient 
habits such as the smoking status came from the physician 
notes. Former smokers were considered as individuals who 
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had smoked at least 100 cigarettes in their lifetime and had 
quit more than 12 months ago.
All the patients gave their informed consent for the uti-
lization of data for scientific purposes.
Pathological Evaluations
Molecular analyses were performed on formalin-fixed 
paraffin-embedded tumor specimens derived from radical sur-
geries or diagnostic procedures. No ad hoc rebiopsies before 
erlotinib were carried out.
DNA was extracted using a commercially available kit 
(QIAamp DNA FFPE Tissue kit, Qiagen, Netherlands) and 
used to amplify exons 18 through 21 of EGFR and exon 2 and 
3 of KRas. DNA was sequenced on both forward and reverse 
directions by capillary electrophoresis using 3500Dx Genetic 
Analyzer (Applied Biosystems, CA).
EGFR of 32 of 47 specimens of the same tumor series 
were re-evaluated by the allele-specific polymerase chain 
reaction test (cobas). DNA was re-extracted with cobas DNA 
sample preparation kit and analyzed with cobas 4800 EGFR 
mutation test (Roche Molecular System Inc., Branchburg, NJ).
FISH assays were performed using the Vysis LSI 
EGFR SpectrumOrange/CEP7 SpectrumGreen Probe (Abbott 
Molecular Inc., Des Plaines, IL). The results were evaluated 
according to the guidelines proposed by Cappuzzo et al.6 
A detailed description of the methodology is provided in 
Supplementary Material and Methods (Supplemental Digital 
Content 1, http://links.lww.com/JTO/A705) and Supplemental 
Table 4 (Supplemental Digital Content 5, http://links.lww.
com/JTO/A709).
Statistical Methods
Clinical and molecular characteristics for both the whole 
population and erlotinib subset were tabulated as counts and per-
centages. Enumeration of response of the patients and the time 
to progression were tabulated as well. Differences in clinical and 
molecular characteristics both for wild-type and mutated EGFR 
and chromosome 7 polysomy groups were compared using the 
chi-square test or the Kruskal-Wallis test as appropriate.
RESULTS
Clinical and Molecular Characteristics 
of the Entire Cohort
One hundred sixty-three patients were identified whose 
tumors were analyzed for EGFR and KRas mutation, EGFR 
amplification, and chromosome 7 copy number variations. 
For clinicopathological characteristics see Table 1. Molecular 
analysis revealed that EGFR mutations were present in at least 
20% of the samples (36 of 163), but only in one patient EGFR 
mutation was not associated to EGFR amplifications or chro-
mosome 7 copy number variations (Table 2).
Patients without EGFR mutations displayed low trysomy 
in 20.8% (34 of 163), high trysomy in 11.6% (19 of 163), low 
TABLE 1.  Clinical Characteristics of the Entire Cohort
No. of Patients (%)
Total 163
Sex
  Female 88 (54.0)
  Male 75 (46.0)
Stage at diagnosis
  I 11 (6.8)
  II 11 (6.8)
  III 69 (42.3)
  IV 71 (43.6)
  Missing 1 (0.6)
Histology
  Adenocarcinoma 149 (91.4)
  Other 14 (8.6)
Smoking status
  Never 65 (39.9)
  Former 59 (36.2)
  Current 31 (19.0)
  Missing 8 (4.9)
TABLE 2.  Molecular Characteristics of the Entire Cohort










Chr. 7 Low 
Trysomy
Chr. 7 High 
Trysomy
Chr. 7 Low 
Polysomy
Chr. 7 High 
Polysomy
EGFR mutation 1 0 9 5 6 5 13 36a
KRas mutation 0 0 2 11 4 6 3 24a
EGFR amplification 9 2 1 0 2 1 5 15a
Chr. 7 low trysomy 5 11 0 34 0 0 0 50
Chr. 7 high trysomy 6 4 2 0 19 0 0 30a
Chr. 7 low polysomy 5 5 1 0 0 17 0 28
Chr. 7 high polysomy 13 3 5 0 0 0 28 46a
Bold indicates single molecular alterations.
a One patient harbors concurrent EGFR mutation, EGFR amplification, and chr.7 high trysomy; two patients concurrent EGFR mutation, EGFR amplification, and chr.7 high 
polysomy, and one patient with EGFR amplification, chr.7 high polysomy, and KRas mutation.
chr.7, chromosome 7; EGFR, epidermal growth factors.
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polysomy in 10.4% (17 of 163), and high polysomy in 17.1% 
(28 of 163) of the cases (Table 2).
In addition, correlations between the EGFR mutation 
and other molecular alterations were evaluated. A strong 
correlation with presence of EGFR amplifications (p ≤ 
0.001) and absence of KRas mutations (p = 0.005) emerged 
(Supplementary Table 1, Supplemental Digital Content 2, 
http://links.lww.com/JTO/A706). An association between 
EGFR mutation and chromosome 7 trysomy (p = 0.019) was 
also observed. Chromosome 7 polysomy was not correlated 
with any of the clinicopathological characteristics analyzed 
(Supplementary Table 2, Supplemental Digital Content 3, 
http://links.lww.com/JTO/A707).
Clinical and Molecular Features 
of the Erlotinib Population
Seventy-three of the 163 patients received EGFR inhib-
itors (Fig. 1). All the patients had advanced disease when 
treated with EGFR-TKI and most of them (94.5%) previously 
received at least one line of chemotherapy (Table 3). In terms 
of molecular features, we observed that 47 (64.4%) patients 
without EGFR mutations were treated (Table 5). Most of them 
had chromosome 7 copy number variations. For a complete 
description of patients see Tables 3 and 4.
All the patients received erlotinib and computed 
tomography scan evaluations were done every 2 to 3 months 
according to the international guidelines. The extent of the 
disease response was determined on the basis of the Response 
Evaluation Criteria in Solid Tumors criteria.
Among the 13 patients with EGFR wild-type and chromo-
some 7 high polysomy, one complete and four partial responses 
were observed, with a median progression-free survival (PFS) of 
9 months (Table 5). Interestingly, only one patient carrying con-
current chromosome 7 high polysomy and KRas mutation pro-
gressed after 2 months. On the contrary, low and high trysomy 
and low polysomy did not show remarkable signs of erlotinib 
activity, with the overall response rates of 7% in the patients with 
low trysomy and 0% in those with high trysomy and low poly-
somy. Logrank analyses revealed a correlation between longer 
PFS and a presence of high polysomy (p = 0.004), in an EGFR 
wild-type background (Supplementary Table 3, Supplemental 
Digital Content 4, http://links.lww.com/JTO/A708).
DISCUSSION
Since their identification in 2004, activating EGFR 
gene mutations have emerged as the most relevant predic-
tor of response to gefitinib or erlotinib. On the contrary, the 
proven EGFR-TKI activity in the EGFR wild-type population 
remains to be addressed. Recently two phase III trials exam-
ined efficacy of erlotinib compared with second-line mono-
chemotherapy in EGFR wild-type NSCLC. In the Tarceva 
Italian Lung Optimization Trial (TAILOR) trial patients 
treated with erlotinib, a worse outcome was obtained com-
pared with patients in the chemotherapy arm.9 In the second 
trial (PROteomic SElection [PROSE]), the authors have pro-
spectively validated a serum proteomic test able to identify 
two subgroups of patients with respectively good and poor 
prognosis. In the first group, erlotinib has shown to be not 
inferior to standard second-line chemotherapy. On the con-
trary, survival of the patients with the test signature associ-
ated with poor prognosis was superior for those treated with 
chemotherapy.10 Taken together, these data suggest that an 
activity of EGFR-TKI in further lines of therapy restricted 
only to a not yet well-identified subgroup of EGFR wild-type 
patients. Indeed EGFR “wild-type” is clearly not a uniform 
entity as terms really define what a disease is not, as opposed 
to what a disease is. We know that, unless otherwise specified, 
the EGFR wild-type lung cancer population must contain 
FIGURE 1.  Study diagram. EGFR, epidermal growth factor.
TABLE 3.  Clinical Features of EGFR-TKI Population
No. of Patients (%)
Total 73
Sex
  Female 39 (54.8)
  Male 33 (45.2)
Stage at diagnosis
  I 5 (6.8)
  II 3 (4.1)
  III 31 (42.5)
  IV 33 (45.2)
  Missing 1 (1.4)
Histology
  Adenocarcinoma 67 (91.8)
  Other 6 (8.2)
Smoking status
  Never 39 (53.4)
  Former 24 (32.9)
  Current 9 (12.3)
  Missing 1 (1.4)
Previous treatment
  No 4 (5.5)
  Yes 69 (94.5)
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anaplastic lymphoma kinase (ALK) gene rearranged, KRas 
mutant, and a whole host of other molecular subpopulations 
with different oncogenic drivers that are still being discov-
ered. Consequently, a diffuse consistent benefit of EGFR-
TKIs seems unlikely in the EGFR wild-type population. As, 
in general, this population has few therapeutic options after 
first-line therapy, defining additional biomarkers that could 
be used together with EGFR mutation testing to help identify 
the group of patients deriving even minimal survival benefit 
from an EGFR-TKI therapy is important. In this context, high 
polisomy of chromosome 7 might be the best biomarker.
Using the Colorado scoring system described by 
Cappuzzo et al. almost 30 to 50% of NSCLC have a gain copy 
number (GCN) of EGFR (FISH-positive NSCLC including 
EGFR gene amplification or high polysomy of chromosome 7).
A meta-analysis of 22 studies comparing the outcome 
of EGFR FISH+ and FISH− patients treated with EGFR-TKI 
confirms that an increased EGFR gene copy number is associ-
ated with a moderate overall survival benefit and a substantial 
PFS benefit.11
However given the association between GCN and 
EGFR mutations, it is critical to analyze GCN data in a direct 
comparison with EGFR mutation status. In the majority of 
studies, this information is not available. Iressa Pan-Asia 
study trial (IPASS) suggested that the apparent PFS benefit 
of gefitinib in patients with a high EGFR copy number was 
due to overlapping EGFR mutations. However, this analysis 
has been conducted on only 55 patients and compared EGFR-
TKI efficacy with that of first-line platinum-based doublets. 
Furthermore, EGFR amplification and high polysomy were 
not analyzed separately.12
Here, we report the data suggesting the need to better 
explore the role of chromosome 7 high polysomy as a helpful 
tool to predict for EGFR-TKI benefit.
In our sample, 17% of the tumors without EGFR muta-
tions are characterized by a high polysomy of chromosome 7. 
Erlotinib led to a disease control in 80% of the patients with 
a 30% of partial response and to a median PFS longer than 9 
months in a heavily treated group of patients.
Data appeared very interesting when compared with 







Patients with EGFR mutations 26 15 (10–22)
  EGFR mutation 1 CR
  EGFR mutation + amplification 1 CR
7 PR
  EGFR mutation + low trysomy 1 PR
  EGFR mutation + high trysomy 4 PR








  EGFR mutation + amplification + high trysomy 1 PR
  EGFR mutation + amplification + high polysomy 1 PR
Patients EGFR wild-type 47
  EGFR amplification 1 CR
  EGFR amplification + high polysomy 1 SD
1 PD
  Total 3 na
  Low trysomy 1 PR
2 SD
11 PD
  Total 14 4 (3–16)
  High trysomy 4 SD
6 PD
1 NA
  Total 11 3 (2, na)
  Low polysomy 5 PD 2 (2–4)





  Total 13 9 (4, na)
  High polysomy + KRas mutation 1 PD
CI, confidence interval; CR, complete response; NA, not available; na, not applicable; 
PD, progressive disease; PFS, progression-free survival; PR, partial response; RECIST, 
response evaluation criteria in solid tumors; SD, stable disease.
TABLE 4.  Molecular Features of EGFR-TKI Population










Chr. 7 Low 
Trysomy
Chr. 7 High 
Trysomy
Chr. 7 Low 
Polysomy
Chr. 7 High 
Polysomy
EGFR mutation 1 0 8 1 5 4 7 24a
KRas mutation 0 0 0 0 0 0 1 1
EGFR amplification 8 0 1 0 1 0 3 11a
Chr. 7 low trysomy 1 0 0 14 0 0 0 15
Chr. 7 high trysomy 5 0 1 0 11 0 0 16a
Chr. 7 low polysomy 4 0 0 0 0 5 0 9
Chr. 7 high polysomy 7 1 3 0 0 0 13 23a
Bold indicates single molecular alteration.
aOne patient harbors concurrent EGFR mutation, EGFR amplification, and chr.7 high trysomy and another patient concurrent EGFR mutation, EGFR amplification, and chr.7 high 
polysomy.
chr.7, chromosome 7; EGFR, epidermal growth factors.
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wild-type patients not otherwise selected and to chemotherapy 
in the same line of treatment.
Our data are certainly limited by the very small sample 
size and by the retrospective nature of analysis but suggest a 
possible role for chromosome 7 high polysomy as a useful tool 
to select EGFR wild-type patients who could possibly benefit 
from an EGFR-TKI treatment.
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